ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Terumo Corp.

Business Summary

Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue628,897M5,784.24M
Gross Profit325,045M2,989.58M
Operating income108,789M1,000.58M
Income before tax106,466M979.21M
Net income85,210M783.71M
EBITDA161,147M1,482.14M
Diluted EPS112.611.03
Dividends Per Share280.25
Total Assets1,241.35B11,498.81M
Total liabilities486,468M4,506.21M
Total equity754,813M6,991.92M
Operating cash flow117,479M1,080.50M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 525,026M 514,164M 587,775M 599,481M 628,897M
Gross Profit 284,901M 261,259M 305,629M 312,203M 325,045M
Operating income 81,703M 90,547M 106,970M 100,621M 108,789M
Income before tax 76,920M 74,881M 106,630M 102,709M 106,466M
Net income 50,676M 55,002M 91,295M 79,470M 85,210M
EBITDA 126,377M 125,018M 149,005M 144,656M 161,147M
Diluted EPS 63.18 71.37 121.03 104.96 112.61
Dividends Per Share 19.50 21 25 27 28
Total Assets 901,685M 1,022.26B 1,081.04B 1,120.79B 1,241.35B
Total liabilities 390,141M 530,735M 530,606M 422,674M 486,468M
Total equity 511,435M 491,421M 550,307M 698,034M 754,813M
Operating cash flow 80,303M 82,888M 114,562M 93,571M 117,479M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 4,372.14M 4,748.13M 5,303.27M 5,405.85M 5,784.24M
Gross Profit 2,372.50M 2,412.64M 2,757.57M 2,815.31M 2,989.58M
Operating income 680.38M 836.17M 965.15M 907.35M 1,000.58M
Income before tax 640.55M 691.50M 962.08M 926.18M 979.21M
Net income 422.00M 507.92M 823.72M 716.62M 783.71M
EBITDA 1,052.40M 1,154.50M 1,344.41M 1,304.44M 1,482.14M
Diluted EPS 0.52 0.65 1.09 0.94 1.03
Dividends Per Share 0.16 0.19 0.22 0.24 0.25
Total Assets 8,022.46M 9,174.02M 10,164.97M 10,125.94M 11,498.81M
Total liabilities 3,471.15M 4,762.94M 4,989.24M 3,818.71M 4,506.21M
Total equity 4,550.33M 4,410.13M 5,174.48M 6,306.49M 6,991.92M
Operating cash flow 668.72M 765.44M 1,033.65M 843.78M 1,080.50M

Valuation Measures

Mar 2020
PER32.64
ROA7.21%
ROE11.73%
Operating margin17.29%
Profit margin13.54%

Key executives

  • President, CEO & Representative Director: Shinjiro Sato
  • Chief Financial & Accounting Officer: Naoki Muto
  • Director & Chief Information Officer: Toshiaki Takagi
  • Chief Clinical & Regulatory Affairs Officer: Kazuhisa Senshu
  • Chief Technology Officer & Executive Officer: Hiroaki Kasukawa

Shareholders

  • Nomura Asset Management Co., Ltd. (8.0%)
  • Massachusetts Financial Services Co. (5.0%)
  • Dai-ichi Life Holdings, Inc. (4.5%)
  • Nikko Asset Management Co., Ltd. (3.9%)
  • Asset Management One Co., Ltd. (3.7%)
  • Daiwa Asset Management Co. Ltd. (3.7%)
  • Meiji Yasuda Life Insurance Co. (3.5%)
  • Mitsubishi UFJ Financial Group, Inc. (2.8%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.4%)
  • The Vanguard Group, Inc. (2.4%)

Contact Details

  • Website:http://www.terumo.co.jp
  • Address: 2-44-1 Hatagaya, Shibuya-Ku, Tokyo, 151-0072, Japan
  • Phone: +81.3.3374.8111

Related Companies

  • Terumo Restricted Stock Compensation Plan
  • Terumo China Holdings Co. Ltd.
  • Essen Technology Pte Ltd.
  • QUIREM Medical BV
  • TP Estate, Inc.
  • Terumo BCT Caribe CA
  • Terumo BCT Portugal Unipessoal Lda.
  • Terumo Russia LLC
  • Terumo BCT Biotechnologies LLC
  • Terumo Colombia Andina SAS
  • Terumo BCT Colombia SA
  • Terumo BCT Uruguay SA
  • Terumo BCT Peru SAC
  • Terumo Panama International, Inc.
  • Terumo Mauritius Holding Ltd.
  • Terumo India Pvt Ltd.
  • Terumo BCT (Hong Kong) Ltd.
  • Terumo Medical (Shanghai) Co. Ltd.
  • Terumo Vietnam Medical Equipment Co. Ltd.
  • MicroVention Europe SARL
  • PT Terumo Indonesia
  • Terumo Singapore Pte Ltd.
  • Terumo Marketing Philippines, Inc.
  • Terumo BCT Vietnam Co. Ltd.
  • Terumo BCT Latin America SA
  • Terumo Medical de Mexico SA de CV
  • Terumo BCT Mexico SA de CV
  • Terumo Malaysia Sdn. Bhd.
  • Terumo BCT Medical Product Trading (Shanghai) Ltd.
  • Terumo BCT Tecnologia Medica Ltda.

Competitors

  • Fresenius SE & Co. KGaA
  • Merit Medical Systems, Inc.
  • Getinge AB Class B
  • Koninklijke Philips N.V.
  • Fresenius Medical Care AG & Co. KGaA
  • Cerus Corporation
  • Silk Road Medical, Inc.
  • Cardiovascular Systems, Inc.
  • CryoLife, Inc.
  • Haemonetics Corporation
  • AngioDynamics, Inc.
  • Stryker Corporation
  • InspireMD, Inc.
  • LeMaitre Vascular, Inc.
  • LivaNova Plc
  • Varian Medical Systems, Inc.
  • Lombard Medical Inc
  • CollPlant Biotechnologies Ltd Sponsored ADR
  • CytoSorbents Corporation
  • Penumbra, Inc.
  • Retractable Technologies, Inc.
  • Guerbet SA
  • ABIOMED, Inc.
  • Cellect Biotechnology Ltd Sponsored ADR
  • Cellular Biomedicine Group, Inc.
  • Nephros, Inc.
  • PSB Industries SA
Last Updated on 23 Sep, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media